Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany

Inclusion Criteria:

• Age ≥18 years as of study index date; the study index date is date of initiation oftreatment with dapagliflozin

• Patient received/receiving treatment with dapagliflozin in accordance with the localdapagliflozin product label for symptomatic chronic heart failure (HF) and attimepoint of dapagliflozin initiation with:

• preserved ejection fraction (HFpEF; EF≥50%) OR mildly reduced ejection fraction (HFmrEF; EF 41-49%)

• OR reduced ejection fraction (HFrEF EF ≤40%)

• Patient is enrolled within 14 to 90 days following initiation of dapagliflozin

• Signed and dated informed consent prior to enrolment in the study

Exclusion Criteria:

• Patient should not be enrolled if he/she is less than 14 days or more than 90 daysfollowing initiation of dapagliflozin

• Prior treatment with dapagliflozin or other SGLT2i treatment

• Initiation of dapagliflozin outside of the local HF label

• Diagnosis of Type 1 diabetes prior to enrolment

• Current or planned participation in a clinical trial using an investigationalmedical product for treating HF

• Patient is involved in the planning and/or conduction of the study

• Hypersensitivity to dapagliflozin or to any of the excipients listed in the SmPC